Repare Therapeutics Inc. — Director's Dealing 2026

Jan 28, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Repare Therapeutics Inc. (RPTX)
CIK: 0001808158
Period of Report: 2026-01-28

Reporting Person: RHOADS ANN D (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-01-28	Common Shares	D	4000	—	Disposed	0	Direct

Footnotes

F1: Pursuant to that certain Arrangement Agreement, dated November 14, 2025 (the "Arrangement Agreement"), by and between the Issuer and XenoTherapeutics, Inc. (the "Parent"), Xeno Acquisition Corp. (the "Purchaser"), and XOMA Royalty Corporation ("XRC"), in exchange for (i) $2.20 in cash per share, plus (ii) one non-transferable contingent value right ("CVR") per share.

F2: Pursuant to the Arrangement Agreement, the Purchaser acquired all of the issued and outstanding common shares of the Issuer for (i) $2.20 in cash per share plus (ii) one CVR per share.